# WHO 5th Ed. Diagnostic Criteria for Subtypes of Acute Myeloid Leukemia (AML)

## Summary Table

| **Type** | **Diagnostic Criteria** |
| --- | --- |
| **AML with defining genetic abnormalities** |  |
| **Acute promyelocytic leukaemia (APL)** | • **PML::RARα fusion** (t(15;17)(q24;q12)) |
| **Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion** | • **RUNX1::RUNX1T1 fusion** (t(8;21)(q22;q22)) |
| **Acute myeloid leukaemia with CBFB::MYH11 fusion** | • **CBFB::MYH11 fusion** (inv(16)(p13q22)) |
| **Acute myeloid leukaemia with NUP98 fusion** | • **NUP98** fusion (various partners) |
| **Acute myeloid leukaemia with RBP::MRTFA fusion** | • **RBM15::MRTFA fusion** (various partners) |
| **Acute myeloid leukaemia with BCR::ABL1 fusion** | • **BCR::ABL1 fusion** (t(9;22)(q34;q11)) |
| **Acute myeloid leukaemia with KMT2A rearrangement** | • **KMT2A** fusion (various partners) |
| **Acute myeloid leukaemia with FLT3 mutation** | • **FLT3** mutation (ITD or TKD) |
| **Acute myeloid leukaemia with CEBPA mutation** | • **CEBPA** mutation (biallelic or single) |
| **Acute myeloid leukaemia with NPM1 mutation** | • **NPM1** mutation |
| **Acute myeloid leukaemia with TP53 mutation** | • **TP53** mutation (biallelic or monoallelic) |
| **AML with other defined genetic alterations** | • Other genetic alterations as per Table 8 |
| **AML with minimal differentiation** | • Blasts are negative (<3%) for MPO and SBB by cytochemistry |
| **AML without maturation** | • ≥3% blasts positive for MPO (by immunophenotyping or cytochemistry) or SBB and negative for NSE by cytochemistry |
| **AML with maturation** | • ≥3% blasts positive for MPO (by immunophenotyping or cytochemistry) or SBB and negative for NSE by cytochemistry |
| **Acute basophilic leukaemia** | • Blasts & immature/mature basophils with metachromasia on toluidine blue staining |
| **Acute myelomonocytic leukaemia** | • ≥20% monocytes and their precursors |
| **Acute monocytic leukaemia** | • ≥80% monocytes and/or their precursors (nonoblasts and/or promonocytes) |
| **Acute erythroid leukaemia (AEL)** | • ≥30% immature erythroid cells (proerythroblasts) |
| **Acute megakaryoblastic leukaemia** | • Blasts express at least one or more of the platelet glycoproteins: CD41 (glycoprotein IIb), CD61 (glycoprotein Ib) |
| **Myeloid neoplasms with TP53 mutation** | • **TP53** mutation (biallelic or monoallelic) |
| **Myeloid neoplasms associated with germline predisposition** | • Germline mutations or predisposing conditions as per Table 10 |

---

## Medical Decision Tree (MDT) for Diagnosing and Subtyping Acute Myeloid Leukaemia (AML)

### **Step 1: Confirm AML Diagnosis**

- **Criteria for AML Diagnosis**: 
  - **Absolute monocyte count**: ≥0.5 × 10^9/L
  - **Relative monocyte count**: ≥10%
  - **Blasts**: ≥20% in peripheral blood and/or bone marrow
  - **Cytogenetic or molecular abnormalities**: One or more documented
  - **Dysplasia**: In at least one lineage
  - **Monocytosis**: If ≥1.0 × 10^9/L, no dysplasia required
  - **Monocytosis**: If ≥0.5 × 10^9/L and <1.0 × 10^9/L, dysplasia required
  - **Monocyte subsets**: Abnormal partitioning required

### **Step 2: Identify Defining Genetic Abnormalities**

- **Check for specific genetic fusions/mutations**:
  1. **PML::RARα fusion**: Confirm APL.
  2. **RUNX1::RUNX1T1 fusion**: Confirm AML with t(8;21).
  3. **CBFB::MYH11 fusion**: Confirm AML with inv(16).
  4. **NUP98 fusion**: Confirm AML with NUP98 rearrangement.
  5. **RBM15::MRTFA fusion**: Confirm AML with RBM15::MRTFA fusion.
  6. **BCR::ABL1 fusion**: Confirm AML with t(9;22).
  7. **KMT2A rearrangement**: Confirm AML with KMT2A fusion.
  8. **FLT3 mutation**: Confirm AML with FLT3-ITD or FLT3-TKD.
  9. **CEBPA mutation**: Confirm AML with biallelic or single CEBPA mutation.
  10. **NPM1 mutation**: Confirm AML with NPM1 mutation.
  11. **TP53 mutation**: Confirm AML with biallelic or monoallelic TP53 mutation.
  12. **Other defined genetic alterations**: Confirm AML with other genetic alterations.

### **Step 3: Evaluate Differentiation Features**

- **Assess differentiation markers**:
  1. **AML with minimal differentiation**:
     - Blasts negative (<3%) for MPO and SBB by cytochemistry.
  2. **AML without maturation**:
     - ≥3% blasts positive for MPO or SBB, negative for NSE.
     - Maturing cells of granulocytic lineage <10%.
  3. **AML with maturation**:
     - ≥3% blasts positive for MPO or SBB.
     - Maturing cells of granulocytic lineage ≥10%.
     - Monocyte lineage cells <20%.
  4. **Acute basophilic leukaemia**:
     - Blasts & immature/mature basophils with metachromasia.
     - Blasts negative for cytochemistry.
     - No expression of strong CD117.
  5. **Acute myelomonocytic leukaemia**:
     - ≥20% monocytes and their precursors.
     - ≥20% maturing granulocytic cells.
     - ≥3% blasts positive for MPO.
  6. **Acute monocytic leukaemia**:
     - ≥80% monocytes and/or their precursors.
     - <20% maturing granulocytic cells.
     - Blasts and promonocytes expressing at least two monocyte markers.
  7. **Acute erythroid leukaemia (AEL)**:
     - ≥30% immature erythroid cells.
     - Bone marrow with erythroid predominance.
  8. **Acute megakaryoblastic leukaemia**:
     - Blasts express at least one or more platelet glycoproteins.

### **Step 4: Evaluate Germline Predisposition**

- **Check for germline mutations or predisposing conditions**:
  1. **Germline mutations**: Review mutations in genes such as CEBPA, DDX41, TP53, RUNX1, etc.
  2. **Predisposing syndromes**: Evaluate for conditions like Fanconi anaemia, Down syndrome, RASopathies, etc.

### **Step 5: Confirm Subtype**

- **Finalize AML subtype** based on:
  - **Genetic abnormalities**.
  - **Differentiation features**.
  - **Germline predisposition**.

---

## Notes:

- **TP53 mutation**: AML with biallelic TP53 mutations is recognized as a distinct entity.
- **Germline predisposition**: AML associated with germline predisposition is recognized as a distinct category, requiring thorough evaluation of family history and genetic testing.

This MDT ensures a comprehensive and structured approach to diagnosing and subtyping AML, incorporating all relevant diagnostic criteria and genetic alterations.
